Immune system modeling devices and methods

Patent metadata

Field	Value
Publication number	US-9535056-B2
Application number	US-81222509-A
Country	US
Kind code	B2
Filing date	Jan 10, 2009
Priority date	Jan 10, 2008
Publication date	Jan 3, 2017
Grant date	Jan 3, 2017

Abstract

Devices and methods are provided for detecting an immune reaction to a test agent using an immune modeling system comprising a barrier component configured to culture a biological barrier, an immune component configured to culture immune cells, and one or more inter-component microfluidic connections between the barrier component and the immune component. The system provides for culturing a biological barrier in the barrier component of the system, culturing immune cells in the immune component of the system, applying the test agent to the biological barrier, and monitoring the immune cells to detect an immune reaction to the test agent.

First claim

What is claimed is:

1. A method of determining whether of a test agent induces a hypersensitivity reaction, comprising:
providing a hypersensitivity modeling device, comprising
i) a first culture compartment containing a biological barrier and comprising dendritic cells;
ii) a second culture compartment containing T-cells; and
iii) one or more inter-compartment microfluidic connections between said first and second compartments, configured to permit the migration of dendritic cells from said first compartment to said second compartment;
culturing said biological barrier, dendritic cells, and T-cells within said device;
flowing culture media between said compartments;
applying a test agent to said biological barrier; and

measuring at least one feature of a hypersensitivity reaction in an immune cell in the device to determine whether there is an increase in the at least one feature of a hypersensitivity reaction after application of the test agent;
wherein, if an increase in the at least one feature of a hypersensitivity reaction in an immune cell in the device is measured after application of the test agent, the test agent is determined to induce hypersensitivity reaction.

2. The method of claim 1 , wherein if an increase in at least one feature of a hypersensitivity reaction in an immune cell in the device is not measured after application of the test agent, the test agent is determined to not induce hypersensitivity reaction.

3. The method of claim 1 , wherein the at least one feature of a hypersensitivity reaction is selected from:
i) the rate of T-cell proliferation;
ii) the amount of T-cell proliferation;
iii) the rate of dendritic cell migration; and
iv) the amount of dendritic cell migration.

4. The method of claim 3 , wherein the at least one feature of a hypersensitivity reaction is the rate of T-cell proliferation.

5. The method of claim 3 , wherein the at least one feature of a hypersensitivity reaction is the amount of T-cell proliferation.

6. The method of claim 3 , wherein the at least one feature of a hypersensitivity reaction is the rate of dendritic cell migration.

7. The method of claim 3 , wherein the at least one feature of a hypersensitivity reaction is the amount of dendritic cell migration.

8. The method of claim 1 , wherein an increase in the at least one feature of a hypersensitivity reaction in an immune cell is measured in the presence of the test agent and the test agent is determined to induce a hypersensitivity reaction.

9. The method of claim 1 , wherein an increase in the at least one feature of a hypersensitivity reaction in an immune cell is not measured in the presence of the test agent and the test agent is determined to not induce a hypersensitivity reaction.

10. The method of claim 1 , wherein said biological barrier is cultured skin.

11. The method of claim 1 , wherein said biological barrier is cultured cornea.

12. The method of claim 1 , wherein said biological barrier is cultured lining of the lungs.

13. The method of claim 1 , wherein said biological barrier is cultured lining of the gastrointestinal tract.

14. The method of claim 1 , wherein said biological barrier is cultured lining of the genitourinary tract.

15. The method of claim 1 , wherein said biological barrier is cultured artificial skin.

16. The method of claim 15 , wherein the biological barrier is cultured artificial skin comprising cultured keratinocytes.

17. The method of claim 1 , wherein said biological barrier comprises a dermal layer.

18. The method of claim 1 , wherein said at least one feature of a hypersensitivity reaction is a feature of delayed type contact hypersensitivity.

19. The method of claim 1 , wherein said test agent comprises a drug, cosmetic, nutriceutical, synthetic chemical, fragrance, lubricant, soap, shampoo, hair product, sunscreen, lotion or oil.

20. The method of claim 3 , wherein the migration of said dendritic cells is monitored through an optical observation component located in said first or second compartment or one or more of said fluidic connections.

21. A method of determining that a test agent induces a hypersensitivity reaction, comprising:
providing a hypersensitivity modeling device, comprising
i) a first culture compartment containing a biological barrier and comprising dendritic cells;
ii) a second culture compartment containing T-cells; and
iii) one or more inter-compartment microfluidic connections between said first and second compartments, configured to permit the migration of dendritic cells from said first compartment to said second compartment;

culturing said biological barrier, dendritic cells, and T-cells within said device;
flowing culture media between said compartments;
applying a test agent to said biological barrier; and
measuring an increase in at least one feature of a hypersensitivity reaction in an immune cell in the device, the at least one feature selected from:
i) the rate of T-cell proliferation;
ii) the amount of T-cell proliferation;
iii) the rate of dendritic cell migration; and
iv) the amount of dendritic cell migration;
to thereby determine that the test agent induces a hypersensitivity reaction.

22. A method of determining that a test agent does not induce a hypersensitivity reaction, comprising:
providing a hypersensitivity modeling device, comprising
i) a first culture compartment containing a biological barrier and comprising dendritic cells;
ii) a second culture compartment containing T-cells; and
iii) one or more inter-compartment microfluidic connections between said first and second compartment, configured to permit the migration of dendritic cells from said first compartment to said second compartment;

culturing said biological barrier, dendritic cells, and T-cells within said device;
flowing culture media between said compartments;
applying a test agent to said biological barrier; and
determining that at least one feature of a hypersensitivity reaction does not occur in an immune cell in the device, the at least one feature selected from:
i) the rate of T-cell proliferation;
ii) the amount of T-cell proliferation;
iii) the rate of dendritic cell migration; and
iv) the amount of dendritic cell migration;
to thereby determine that the test agent does not induce a hypersensitivity reaction.

Assignees

• Yarmush Martin L
• Freedman Robert
• Del Bufalo Aurelia
• Teissier Silvia
• Meunier Jean-Roch
• Oreal

Inventors

• Yarmush Martin L
• Freedman Robert
• Del Bufalo Aurelia
• Teissier Silvia
• Meunier Jean-Roch

Classifications

• G01N33/505 Primary

  involving T-cells · CPC title

• C12M23/16

  Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093) · CPC title

• C12M23/58

  Reaction vessels connected in series or in parallel (combinations of bioreactors with other apparatus, C12M43/00) · CPC title

• G01N33/5044

  involving specific cell types · CPC title